An imidazo[1,2-a]pyridine derivative, its preparation method and application

By synthesizing imidazo[1,2-a]pyridine derivatives, the shortcomings of existing drugs in terms of cardiovascular damage risk and anti-tumor activity have been overcome, achieving effective inhibition of HDAC6 and cardiomyocyte protection, which is suitable for the preparation of anti-gastrointestinal tumor and cardioprotective drugs.

CN118359611BActive Publication Date: 2026-11-17ZHENGZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410435434.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-11
Publication Date
2026-11-17
Estimated Expiration
2044-04-11

AI Technical Summary

Technical Problem

Existing drugs for the treatment of gastrointestinal tumors are insufficient in terms of cardiovascular damage risk, and there is a lack of HDAC6 inhibitors that have both anti-tumor activity and cardioprotective effects.

Method used

We designed and synthesized imidazo[1,2-a]pyridine derivatives, and prepared compounds with inhibitory activity against HDAC6 and protective effects on cardiomyocytes through specific reaction steps.

Benefits of technology

This compound exhibits good inhibitory effects on HDAC6, effectively inhibiting the proliferation of gastrointestinal tumor cells while causing no damage to cardiomyocytes. It has low toxicity and high activity, making it suitable for developing novel anti-gastrointestinal tumor drugs with low cardiovascular damage risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

This invention belongs to the field of medicinal chemistry, specifically relating to an imidazo[1,2-a]pyridine derivative, its preparation method, and its applications. The imidazo[1,2-a]pyridine derivative provided by this invention is a novel type of compound with a novel structure synthesized for the first time. Experiments have confirmed that this type of compound exhibits good inhibitory activity against histone deacetylase 6 (HDAC6) and good inhibitory activity against gastrointestinal tumor cells, while also showing good protective activity against cardiomyocytes, exhibiting low toxicity and high activity. Experimental verification showed that when gastrointestinal tumor cell lines were transplanted into nude mice, the imidazo[1,2-a]pyridine derivative provided by this invention could inhibit tumor proliferation at high concentrations without damaging myocardial tissue. Therefore, it can provide a potential lead compound for the development of novel anti-gastrointestinal tumor drugs with low cardiovascular damage risk.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medicinal chemistry technology, specifically relating to an imidazo[1,2-a]pyridine derivative, its preparation method, and its application. Background Technology

[0002] Gastrointestinal tumors are significant systemic diseases affecting human health, and the cardiovascular diseases induced by their cardiotoxicity during treatment are receiving increasing attention. Therefore, there is an urgent clinical need for novel therapeutic drugs for gastrointestinal tumors with low risk of cardiovascular damage.

[0003] Histone deacetylase 6 (HDAC6), a key protease regulating gene transcription, has been shown to be highly expressed in various gastrointestinal tumor tissues and is closely related to the clinicopathological features of patients. Meanwhile, myocardial injury is a common feature and major cause of various cardiovascular diseases. Inhibiting HDAC6 can prevent the occurrence of myocardial injury at different pathophysiological levels.

[0004] Therefore, the design and development of novel HDAC6 inhibitors with highly effective anti-tumor activity and cardioprotective effects have a very broad application prospect in the future treatment of gastrointestinal tumors. Summary of the Invention

[0005] In order to overcome the shortcomings of the prior art, the present invention aims to provide an imidazo[1,2-a]pyridine derivative, which has good inhibitory activity against HDAC6, can inhibit the proliferation of gastrointestinal tumor cells, and has a protective effect on cardiomyocytes.

[0006] The present invention also aims to provide a method for preparing the above-mentioned imidazo[1,2-a]pyridine derivatives, wherein the reaction conditions are mild and suitable for the preparation of the compounds.

[0007] Another object of the present invention is to provide the application of the above-mentioned imidazo[1,2-a]pyridine derivatives.

[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0009] An imidazo[1,2-a]pyridine derivative, having the structure shown in Formula I, Formula II, or Formula III:

[0010]

[0011]

[0012] In Formulas I, II, and III, n1 and n2 are 0 or 1; X is CH or N; R1 is one of H, 2-F, 2-Cl, or 2-CH3; and R2 is one of 4-CH3, 3-CH3, 2-CH3, 4-CH2CH3, 2-CH2CH3, 4-CH(CH3)2, 4-OCH3, 2-OCH3, 2,4-2OCH3, 4-F, 3-F, 2-F, 3-Cl, 2-Cl, or 3-Br.

[0013] To ensure the compound's inhibitory activity against HDAC6, its anti-proliferative effect on gastrointestinal tumor cells, and its protective effect on cardiomyocytes, the imidazo[1,2-a]pyridine derivative is selected from compounds with the following structures:

[0014]

[0015]

[0016] The preparation method of the above-mentioned imidazo[1,2-a]pyridine derivatives, the preparation method of the imidazo[1,2-a]pyridine derivatives with the structure shown in Formula I, includes the following steps:

[0017] (1) 2-Amino-5-bromonicaraldehyde, chloroacetaldehyde, and a first good solvent were mixed to carry out the first cyclization reaction, yielding compound A with the structural formula:

[0018] (2) Compound A, phenylboronic acids with different substitutions, a first catalyst, and a second good solvent were mixed and subjected to a first coupling reaction to obtain compound B, with the structural formula shown below.

[0019] (3) Compound B, methyl p-amino(substituted)benzoate or methyl aminopyridinecarboxylate, a second catalyst, a first reducing agent, sodium hydroxide, and a third good solvent are mixed to carry out a first substitution reaction to obtain compound C, with the structural formula […].

[0020] (4) Compound C, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine, the third catalyst and the fourth good solvent are mixed and subjected to the first condensation reaction to obtain an imidazo[1,2-a]pyridine derivative having the structure shown in Formula I;

[0021] The method for preparing the imidazo[1,2-a]pyridine derivative with the structure shown in Formula II includes the following steps:

[0022] (a) A second substitution reaction was carried out by mixing 6-bromoimidazolo[1,2-a]pyridine-8-amine, methyl p-bromomethylbenzoate, a fourth catalyst, and a fifth good solvent to give compound D, with the structural formula [insert structural formula here].

[0023] (b) Compound D, phenylboronic acids with different substitutions, a first catalyst, and a second good solvent were mixed and subjected to a second coupling reaction to obtain compound E, with the structural formula [insert structural formula here].

[0024] (c) Compound E, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine, a third catalyst and a fourth good solvent were mixed and subjected to a second condensation reaction to obtain an imidazo[1,2-a]pyridine derivative having the structure shown in Formula II;

[0025] The method for preparing the imidazo[1,2-a]pyridine derivative with the structure shown in Formula III includes the following steps:

[0026] ① A mixture of 6-bromoimidazolo[1,2-A]pyridine-8-carboxylic acid, amines with different substitutions, a first catalyst, and a second good solvent is subjected to a third condensation reaction to yield compound F, with the structural formula:

[0027] ② Compound F, phenylboronic acids with different substitutions, the first catalyst, and the second good solvent are mixed and subjected to a third coupling reaction to obtain compound G, with the structural formula as follows:

[0028] ③ The compound G, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine, the third catalyst and the fourth good solvent are mixed and subjected to the fourth condensation reaction to obtain an imidazo[1,2-a]pyridine derivative with the structure shown in Formula III.

[0029] Preferably, the temperature of the first cyclization reaction is 80–100°C, and the reaction time is 4–8 h; the temperature of the first coupling reaction, the second coupling reaction, and the third coupling reaction is 75–100°C, and the reaction time is 3–12 h; the temperature of the first substitution reaction and the second substitution reaction is 0–25°C, and the reaction time is 7–12 h; the temperature of the first condensation reaction, the second condensation reaction, and the third condensation reaction is room temperature (15–30°C), and the reaction time is 2–10 h.

[0030] Preferably, the first good solvent, the second good solvent, the third good solvent, and the fourth good solvent are each independently selected from one or more of ethanol, methanol, 1,2-dichloroethane, dichloromethane, tetrahydrofuran, N,N-dimethylformamide, dioxane, and water.

[0031] Preferably, the first catalyst is selected from one or more of bis(triphenylphosphine)palladium dichloride, tetratriphenylphosphine palladium, palladium acetate, potassium carbonate, and cesium carbonate; the second catalyst is selected from one or more of acetic acid, sodium borohydride acetate, sodium triacetoxyborohydride, and sodium borohydride.

[0032] Preferably, the third catalyst is selected from one or more of HATU, DIPEA, DCC, and EDCI; and the fourth catalyst is selected from one or more of sodium hydride, lithium hydroxide, and potassium hydroxide.

[0033] The application of imidazo[1,2-a]pyridine derivatives as described above in the preparation of HDAC6 inhibitors.

[0034] The application of imidazo[1,2-a]pyridine derivatives as described above in the preparation of drugs for treating gastrointestinal tumors.

[0035] The application of imidazo[1,2-a]pyridine derivatives as described above in the preparation of cardioprotective drugs.

[0036] The beneficial effects of the technical solution of this invention are as follows:

[0037] I. The imidazo[1,2-a]pyridine derivatives provided by this invention represent a novel type of compound with a novel structure synthesized for the first time in this invention. Experiments have confirmed that these compounds exhibit good inhibitory activity against histone deacetylase 6 (HDAC6) and good inhibitory activity against gastrointestinal tumor cells, while also showing good protective activity against cardiomyocytes, exhibiting low toxicity and high activity. Experimental results show that when gastrointestinal tumor cell lines are transplanted into nude mice, the imidazo[1,2-a]pyridine derivatives provided by this invention can inhibit tumor proliferation at high concentrations without damaging myocardial tissue. Therefore, they can provide potential lead compounds for the development of novel anti-gastrointestinal tumor drugs with low cardiovascular damage risk.

[0038] Second, the present invention also provides a method for preparing the above-mentioned imidazo[1,2-a]pyridine derivatives, which is simple in steps, convenient in operation, and has the prospect of large-scale industrial production.

[0039] Thirdly, this invention also provides applications of the above-mentioned imidazo[1,2-a]pyridine derivatives, specifically in the preparation of HDAC6 inhibitors, drugs for treating gastrointestinal tumors, and cardioprotective drugs. Experimental verification shows that the imidazo[1,2-a]pyridine derivatives provided by this invention have good inhibitory activity against HDAC6 and can inhibit the proliferation of gastrointestinal tumor cells, while also protecting cardiomyocytes. Therefore, these compounds can be used to prepare drugs for treating gastrointestinal tumors or cardioprotective drugs, and are particularly suitable for development as small molecule inhibitors of HDAC6, possessing good potential for new drug development. Detailed Implementation

[0040] The technical solution of the present invention will be further described below with reference to specific embodiments, but this does not constitute a limitation on the present invention. Unless otherwise specified, the test materials involved in the following embodiments and experimental examples can be obtained through conventional commercial channels.

[0041] Example 1

[0042] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is as follows:

[0043] (1) Weigh 10 mmol of 2-amino-5-bromonicaraldehyde into a round-bottom flask containing 50 mL of ethanol; add 20 mmol of chloroacetaldehyde while stirring, reflux at 90 °C for 5 h, and monitor the reaction by TLC; after the reaction is complete, remove the ethanol by evaporation, wash with ethyl ester, and obtain compound A-1, with the following structural formula:

[0044] (2) Compound A-1 (5 mmol), 4-methylphenylboronic acid (7.5 mmol), bis(triphenylphosphine)palladium dichloride (0.5 mmol), and potassium carbonate (7.5 mmol) were added to a round-bottom flask containing 1,4-dioxane / water (30 mL / 3 mL); under nitrogen protection, the mixture was refluxed at 90 °C for 5 h, and monitored by TLC; after the reaction was completed, 1,4-dioxane was vortexed off, the residue was dissolved in ethyl acetate, and the ethyl acetate phase was concentrated to obtain compound B-1, with the following structural formula:

[0045] (3) Weigh compound B-1 (5 mmol) into a methanol (30 mL) solution of methyl 4-aminopyridinecarboxylate (5 mmol); stir overnight at room temperature under acetic acid catalysis; add sodium borohydride (15 mmol), continue stirring for 3–5 h, and monitor by TLC; after the reaction is complete, quench the reaction system in an aqueous ammonium chloride solution, dissolve in ethyl acetate, concentrate the ethyl acetate phase, transfer to a round-bottom flask containing methanol (15 mL), add 3–5 mL of 33% sodium hydroxide / water solution, reflux at 75 °C for 1 h, and monitor by TLC; after the reaction is complete, remove the methanol, acidify with hydrochloric acid, and filter to obtain compound C-1, structural formula

[0046] (4) Weigh out compounds C-1 (1 mmol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (1 mmol), and HATU (1.2 mmol) into a round-bottom flask containing DMF (10 mL); add DIPEA (1.5 mmol) with stirring, and react at room temperature for 2 h, monitoring with TLC; after the reaction is complete, add the reaction system to water, and a solid slowly precipitates out. Filter the solid and transfer it to a round-bottom flask containing dichloromethane (10 mL). Slowly add concentrated hydrochloric acid until complete deprotection; remove the dichloromethane by swirl, add sodium bicarbonate / water solution with stirring at room temperature, adjust the pH to weakly acidic, and filter to obtain the imidazo[1,2-a]pyridine derivative of Example 1, a white solid with a melting point of 219–220 °C, and the structural formula is: (Compound 1). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.90 (s, 1H), 8.81 (d, J = 25.0Hz, 2H), 8.40 (s, 1H), 7. 99(s,1H),7.77-7.22(m,8H),6.65(d,J=8.3Hz,1H),4.91(s,2H),2.33(s,3H). 13 CNMR(100MHz,DMSO-d6)δ164.3,160.5,148.0,143.4,137.5,136.0,134.5,133.5,130.2,128 .4,126.7,125.2,122.7,121.3,117.2,114.5,108.0,31.6,30.3,21.1.HR-MS(ESI),calcd,C 21 H 19 N5O2,[M+H] + m / z:374.1617, found:374.1615.

[0047] Example 2

[0048] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that in Example 1, except that methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-amino-3-fluorophenylcarboxylate, otherwise the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 2 was prepared as a white solid with a melting point >300℃, and its structural formula is as follows. (Compound 2). The structural analysis results are as follows: 1H NMR (400MHz, DMSO-d6) δ10.96(s,1H),9.19(s,1H),8.85(s,1H),8.30(d,J=37.7Hz,3H),7.62(d ,J=7.7Hz,2H),7.49-7.27(m,4H),7.04(s,1H),6.90(d,J=8.6Hz,1H),4.87(s,2H),2.37(s,3H). 13 C NMR (100MHz, DMSO-d6) δ163.5,148.7,138.4,138.2,138.0,131.9,129.9,128.7,126. 6,124.4,124.2,124.0,120.3,115.9,113.1,111.4,41.6,20.7.HR-MS(ESI),calcd.C 22 H 19 FN4O2,[M+H] + m / z:391.1570, found:391.1575.

[0049] Example 3

[0050] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-amino-3-chlorophenylcarboxylate, and the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 3 was prepared as a white solid with a melting point of 221-222℃, and its structural formula is as follows. (Compound 3). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.98(s,1H),9.16(s,1H),8.87(s,1H),8.39-8.07(m,3H),7.71(s, 1H),7.65-7.48(m,3H),7.36(d,J=7.7Hz,2H),7.06-6.81(m,2H),4.93(s,2H),2.37(s,3H). 13 C NMR(100MHz,DMSO-d6)δ163.2,145.5,138.4,132.0,129.9,128.5,128.0,127.0,1 26.6,124.4,124.1,121.2,117.6,115.8,110.9,41.8,20.7.HR-MS(ESI),calcd.C 22 H 19 ClN4O2,[M+H] +m / z:407.1275,found:407.1281.

[0051] Example 4

[0052] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-amino-3-methylphenylcarboxylate, and the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 4 was prepared as a white solid with a melting point of 216-217°C, and its structural formula is as follows. (Compound 4). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.78(s,1H),9.14(s,1H),8.70(s,1H),8.34-8.11(m,3H) ,7.70-7.29(m,6H),6.62(t,J=26.7Hz,2H),4.86(s,2H),2.36(s,3H),2.21(s,3H). 13 C NMR(100MHz,DMSO-d6)δ164.8,147.9,138.4,132.0,130.0,128.9,128.6,126.6, 126.0,124.4,121.4,120.0,115.8,108.6,41.9,20.7,18.1.HR-MS(ESI),calcd.C 23 H 22 N4O2,[M+H] + m / z:387.1821,found:387.1820.

[0053] Example 5

[0054] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, and the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 5 was prepared as a white solid with a melting point of 216-217℃, and its structural formula is as follows. (Compound 5). The structural analysis results are as follows: 1H NMR(400MHz,DMSO-d6)δ10.77(s,1H),8.80(s,1H),8.70(s,1H),8.01(s,1H),7.64(s,1H),7.58- 7.44(m,5H),7.28(d,J=7.9Hz,2H),6.87(s,1H),6.66(d,J=8.6Hz,2H),4.71(s,2H),2.33(s,3H). 13 C NMR (100MHz, DMSO-d6) δ164.9,151.0,142.8,137.1,133.9,132.9,129.7,128.3,127. 4,126.2,124.8,122.3,121.2,119.8,114.1,111.3,41.8,20.6.HR-MS(ESI),calcd.C 22 H 20 N4O2,[M+H] + m / z:373.1665, found:373.1662.

[0055] Example 6

[0056] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 3-methylphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 6 was prepared, a white solid with a melting point >300℃, and the structural formula is as follows. (Compound 6). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),9.20(d,J=15.0Hz,1H),8.70(s,1H),8.36(d,J=14.8Hz,1H),8.25(d,J=1 3.4Hz,2H),7.66-7.19(m,8H),6.74(dd,J=14.8,8.1Hz,2H),4.82(d,J=14.5Hz,2H),2.43(s,1H),2.39(s,2H). 13 C NMR(100MHz,DMSO-d6)δ164.7,150.2,138.7,138.1,134.9,129.4,129.0,128.6,1 27.4,124.8,124.4,123.9,120.4,115.8,111.6,41.8,21.1.HR-MS(ESI),calcd.C22 H 20 N4O2,[M+H] + m / z:373.1665, found:373.1669.

[0057] Example 7

[0058] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2-methylphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 7 was prepared, a white solid with a melting point of 210-211℃, and the structural formula is as follows. (Compound 7). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),8.71(s,1H),8.23(s,1H),8.03(s,1H),7.64-7. 44(m,3H),7.33(s,2H),7.28(s,2H),6.66(d,J=8.2Hz,2H),4.76(s,2H),2.14(s,3H). 13 C NMR (100MHz, DMSO-d6) δ164.7,150.4,136.1,135.6,130.7,129.7,128.5,128.3,127. 9,127.3,126.2,125.2,124.9,120.1,115.1,111.5,41.6,19.8.HR-MS(ESI),calcd.C 22 H 20 N4O2,[M+H] + m / z:373.1665,found:373.1667.

[0059] Example 8

[0060] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 4-ethylphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 8 was prepared, a white solid with a melting point of 217-218℃, and the structural formula is as follows. (Compound 8). The structural analysis results are as follows: 1H NMR(400MHz,DMSO-d6)δ10.73(s,1H),8.79(s,1H),8.65(s,1H),8.00(s,1H),7.62(s,1H),7.56-7.40(m,5H),7.31( d,J=7.5Hz,2H),6.84(s,1H),6.64(d,J=8.4Hz,2H),4.70(d,J=4.8Hz,2H),2.70-2.58(m,2H),1.19(t,J=7.5Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ164.9,151.0,143.4,142.9,134.2,133.1,128.8,128.4,127.5, 126.3,124.7,122.3,121.0,119.8,114.1,111.3,41.7,27.7,15.5.HR-MS(ESI),calcd.C 23 H 22 N4O2,[M+H] + m / z:387.1821,found:387.1827.

[0061] Example 9

[0062] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2-ethylphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 9 was prepared, a white solid with a melting point of 213-214℃, and the structural formula is as follows. (Compound 9). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.76(s,1H),8.69(s,1H),8.49(s,1H),7.98(s,1H),7.62-7.45(m ,3H),7.22(s,2H),6.84(s,1H),6.68-6.52(m,4H),4.66(s,2H),3.79(s,3H),3.63(s,3H). 13C NMR(100MHz,DMSO-d6)δ160.4,157.3,151.0,142.6,132.7,130.6,128.2,126.0,123 .8,122.4,119.7,118.6,113.7,111.3,105.4,99.0,55.4,41.6.HR-MS(ESI),calcd.C 23 H 22 N4O4,[M+H] + m / z:419.1719,found:419.1720.

[0063] Example 10

[0064] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 4-isopropylphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 10 was prepared, a white solid with a melting point of 209-210℃, and the structural formula is as follows. (Compound 10). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.78(s,1H),8.68(s,1H),8.50(s,1H),8.05(s,1H),7.73(s,1H),7.51(d,J=8.3Hz,2H),7.33(d,J=9.7Hz,2H) ,7.22(dd,J=13.3,6.6Hz,2H),7.14(s,1H),6.90(s,1H),6.60(d,J=8.3Hz,2H),4.72(s,2H),2.45-2.31(m,2H),0.90(t,J=7.4Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ165.3,151.2,147.6,142.2,137.1,132.1,130.4,129.3,128.8,126.5 ,125.4,124.7,120.3,114.7,111.8,42.0,35.0,31.6,30.3,25.9,15.7.HR-MS(ESI),calcd.C 23 H 22 N4O2,[M+H] + m / z:387.1821,found:387.1822.

[0065] Example 11

[0066] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 4-methoxyphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 11 was prepared, a white solid with a melting point of 216-217℃, and the structural formula is as follows. (Compound 11). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.76(s,1H),8.72(d,J=18.7Hz,2H),7.98(s,1H),7.62(s,1H),7.53(s,2H),7.51(s,2 H),7.43(s,1H),7.04(d,J=8.5Hz,2H),6.85(s,1H),6.66(d,J=8.5Hz,2H),4.70(d,J=5.7Hz,2H),3.79(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.4,159.5,151.5,143.3,133.5,129.6,128.8,128.0,1 25.0,122.3,121.5,120.3,115.1,114.5,111.8,55.7,42.3.HR-MS(ESI),calcd.C 22 H 20 N4O3,[M+H] + m / z:389.1614, found:389.1620.

[0067] Example 12

[0068] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2-methoxyphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 12 was prepared, a white solid with a melting point of 209-210℃, and the structural formula is as follows. (Compound 12). The structural analysis results are as follows: 1H NMR (400MHz, DMSO-d6) δ10.77(s,1H),8.63(d,J=40.0Hz,2H),8.03(s,1H),7.66(s,1H),7.52(d,J=8.6Hz ,2H),7.39-7.28(m,3H),7.14-6.98(m,2H),6.87(s,1H),6.62(d,J=8.6Hz,2H),4.69(s,2H),3.64(s,3H). 13 C NMR (100MHz, DMSO-d6) δ165.4,156.8,151.4,142.8,132.7,130.6,129.9,128.7,126. 4,124.8,123.3,121.3,120.2,114.5,112.3,111.8,55.9,42.1.HR-MS(ESI),calcd.C 22 H 20 N4O3,[M+H] + m / z:389.1614, found:389.1612.

[0069] Example 13

[0070] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2,4-dimethoxyphenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 13 was prepared, a white solid with a melting point of 213-214℃, and the structural formula is as follows. (Compound 13). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.76(s,1H),8.69(s,1H),8.49(s,1H),7.98(s,1H),7.62-7.45(m ,3H),7.22(s,2H),6.84(s,1H),6.68-6.52(m,4H),4.66(s,2H),3.79(s,3H),3.63(s,3H). 13 C NMR(100MHz,DMSO-d6)δ160.4,157.3,151.0,142.6,132.7,130.6,128.2,126.0,123 .8,122.4,119.7,118.6,113.7,111.3,105.4,99.0,55.4,41.6.HR-MS(ESI),calcd.C 23H 22 N4O4,[M+H] + m / z:419.1719,found:419.1720.

[0071] Example 14

[0072] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 4-fluorophenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 14 was prepared, a white solid with a melting point of 220-221℃, and the structural formula is as follows. (Compound 14). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.80(s,1H),9.10(s,1H),8.69(s,1H),8.26(s,1H),8.06(d,J=32.7Hz,2H),7.80- 7.64(m,2H),7.53(d,J=8.4Hz,2H),7.39(t,J=8.5Hz,2H),7.18(s,1H),6.70(d,J=8.3Hz,2H),4.77(s,2H). 13 C NMR (100MHz, DMSO-d6) δ164.7,163.6,161.2,150.4,139.1,131.9,128.9,128.9,128. 3,126.9,125.5,124.2,120.3,116.4,116.1,115.5,111.5,41.8.HR-MS(ESI),calcd.C 21 H 17 FN4O2,[M+H] + m / z:377.1414,found:377.1411.

[0073] Example 15

[0074] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 3-fluorophenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 15 was prepared, a white solid with a melting point of 226-227℃, and the structural formula is as follows. (Compound 15). The structural analysis results are as follows: 1H NMR (400MHz, DMSO-d6) δ10.82(s,1H),9.30(s,1H),8.45-8.18(m,3H),7.75-7.49(m,5H),7.33(s,1H),6.73(d,J=7.8Hz,2H),4.81(s,2H). 13 CNMR(100MHz,DMSO-d6)δ164.7,163.9,161.5,150.1,138.0,137.2,131.5,129.6,128.3,127. 5,125.3,124.8,124.1,123.0,120.4,116.0,113.9,113,6,111.6,41.8.HR-MS(ESI),calcd.C 21 H 17 FN4O2,[M+H] + m / z:377.1414,found:377.1416.

[0075] Example 16

[0076] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2-fluorophenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 16 was prepared, a white solid with a melting point of 214-215℃, and the structural formula is as follows. (Compound 16). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ10.78(s,1H),8.84(s,1H),8.71(s,1H),8.16(s,1H),7.84(s,1H),7.6 1-7.42(m,5H),7.35(dd,J=15.8,8.5Hz,2H),6.96(s,1H),6.65(d,J=8.5Hz,2H),4.73(s,2H). 13 C NMR(100MHz,DMSO-d6)δ164.8,160.4,157.9,150.7,141.4,130.6,130.3,128.3,126.5 ,125.2,124.4,124.2,120.8,120.0,116.4,116.2,114.7,111.3.HR-MS(ESI),calcd.C 21 H 17 FN4O2,[M+H] +m / z:377.1414,found:377.1419.

[0077] Example 17

[0078] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 3-chlorophenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 17 was prepared, a white solid with a melting point of 209-210℃, and the structural formula is as follows. (Compound 17). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.79(s,1H),8.93(s,1H),8.73(s,1H),8.00(s,1H),7.71(s,1H),7.66(s,1H),7.58(d,J=7.7Hz,1H ),7.53(d,J=4.0Hz,1H),7.52-7.48(m,2H),7.44(d,J=8.0Hz,1H),6.85(s,1H),6.67(d,J=8.7Hz,2H),4.71(d,J=5.9Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ164.8,150.9,143.0,139.1,133.9,133.4,130.9,128.3,127.7,1 27.5,126.1,125.0,123.4,123.3,120.8,119.9,114.3,111.4,41.8.HR-MS(ESI),calcd.C 21 H 17 ClN4O2,[M+H] + m / z:393.1118,found:393.1116.

[0079] Example 18

[0080] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2-chlorophenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 18 was prepared, a white solid with a melting point of 209-211℃, and the structural formula is as follows. (Compound 18). The structural analysis results are as follows: 1H NMR(400MHz,DMSO-d6)δ10.81(s,1H),8.80(s,1H),8.72(s,1H),8.24(s,1H),8 .00(s,1H),7.75-7.41(m,7H),7.05(s,1H),6.65(d,J=8.3Hz,2H),4.75(s,2H). 13 C NMR(100MHz,DMSO-d6)δ164.7,150.5,140.1,135.1,131.9,131.6,130.3,130.0,1 28.2,127.8,125.9,125.4,125.2,120.1,115.1,111.5,41.6.HR-MS(ESI),calcd.C 21 H 17 ClN4O2,[M+H] + m / z:393.1118,found:393.1122.

[0081] Example 19

[0082] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 1, except that: 4-methylphenylboronic acid in step (2) is replaced with 2-bromophenylboronic acid, and methyl 4-aminopyridinecarboxylate in step (3) is replaced with methyl 4-aminobenzoate, the rest is the same as in Example 1. The imidazo[1,2-a]pyridine derivative of Example 19 was prepared, a white solid with a melting point of 209-210℃, and the structural formula is as follows. (Compound 19). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H),8.92(s,1H),8.70(s,1H),8.00(s,1H),7.68(d,J=1 8.7Hz,2H),7.60-7.40(m,6H),6.84(s,1H),6.67(d,J=8.5Hz,2H),4.71(d,J=5.6Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ165.4,151.4,143.5,139.6,134.4,133.9,131.4,128.8,1 28.1,126.6,125.5,123.8,121.3,120.4,114.8,111.9,42.3.HR-MS(ESI),calcd.C 21 H 17 BrN4O2,[M+H] +m / z:437.0613,found:437.0611.

[0083] Example 20

[0084] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which includes the following steps:

[0085] (a) Weigh 10 mmol of 6-bromoimidazolo[1,2-a]pyridine-8-amine into a flask containing 50 mL of tetrahydrofuran; add sodium hydride (12 mmol) in portions with stirring in an ice bath; after half an hour, add methyl p-bromomethylbenzoate (10 mmol), continue stirring for 3–5 hours, and monitor the reaction by TLC; after the reaction is complete, evaporate the tetrahydrofuran, dissolve the residue in ethyl acetate, concentrate the ethyl acetate phase to give compound D, with the structure [structure omitted].

[0086] (b) Compound D (5 mmol), 4-methylphenylboronic acid (7.5 mmol), bis(triphenylphosphine)palladium dichloride (0.5 mmol), and potassium carbonate (7.5 mmol) were weighed into a round-bottom flask containing 1,4-dioxane / water (30 mL / 3 mL); under nitrogen protection, the mixture was refluxed at 90 °C for 5 h, and monitored by TLC; after the reaction was complete, 1,4-dioxane was evaporated, the residue was dissolved in ethyl acetate, the ethyl ester phase was concentrated, and transferred to a round-bottom flask containing methanol (15 mL). 3–5 mL of 33% sodium hydroxide / water solution was added, and the mixture was refluxed at 75 °C for 1 h, and monitored by TLC; after the reaction was complete, methanol was evaporated, acidified with hydrochloric acid, and filtered to obtain compound E-1, with the structural formula [insert structural formula here].

[0087] (c) Weigh out compounds E-1 (1 mmol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (1 mmol), and HATU (1.2 mmol) into a round-bottom flask containing DMF (10 mL); add DIPEA (1.5 mmol) with stirring, and react at room temperature for 2 h, monitoring with TLC; after the reaction is complete, add the reaction system to water, and a solid slowly precipitates out. Filter the solid and transfer it to a round-bottom flask containing dichloromethane (10 mL). Slowly add concentrated hydrochloric acid until complete deprotection; remove the dichloromethane by swirl, add sodium bicarbonate / water solution with stirring at room temperature, adjust the pH to weakly acidic, and filter to obtain the imidazo[1,2-a]pyridine derivative of Example 20, a white solid with a melting point >300 °C, and the structural formula is: (Compound 20). The structural analysis results are as follows: 1H NMR(400MHz,DMSO-d6)δ8.07(s,1H),7.84(s,2H),7.68(s,2H),7.52-7.31(m,5H),7. 22(s,2H),6.77(s,1H),6.21(s,1H),4.54(s,2H),2.29(s,3H).HR-MS(ESI),calcd.C 22 H 20 N4O2,[M+H] + m / z:373.1665, found:373.1662.

[0088] Example 21

[0089] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that in Example 20, except that 4-methylphenylboronic acid in step (b) is replaced with 3-methylphenylboronic acid, otherwise the same as in Example 20. The imidazo[1,2-a]pyridine derivative of Example 21 was prepared as a white solid with a melting point of 210-211°C, and its structural formula is as follows. (Compound 21). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ11.15(s,1H),9.01(s,1H),8.12(s,1H),7.88(s,1H),7.71(d,J=8.1Hz,2H),7.51(s,2H),7.49( s,1H),7.37-7.27(m,3H),7.15(d,J=3.8Hz,1H),6.90(t,J=6.0Hz,1H),6.27(s,1H),4.63(d,J=5.9Hz,2H),2.34(s,3H). 13 C NMR(100MHz,DMSO-d6)δ164.2,143.0,138.0,137.8,137.6,136.0,131.3,130.8,128.8, 128.1,127.1,127.0,126.8,123.5,114.5,112.2,97.5,45.5,21.0.HR-MS(ESI),calcd.C 22 H 20 N4O2,[M+H] + m / z:373.1665,found:373.1666.

[0090] Example 22

[0091] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 20, except that 4-methylphenylboronic acid in step (b) is replaced with 2-methylphenylboronic acid, otherwise the same as in Example 20. The imidazo[1,2-a]pyridine derivative of Example 22 was prepared as a white solid with a melting point of 210-211°C, and its structural formula is as follows. (Compound 22). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ11.15(s,1H),9.01(s,1H),8.12(s,1H),7.88(s,1H),7.71(d,J=8.1Hz,2H),7.51(s,2H),7.49( s,1H),7.37-7.27(m,3H),7.15(d,J=3.8Hz,1H),6.90(t,J=6.0Hz,1H),6.27(s,1H),4.63(d,J=5.9Hz,2H),2.34(s,3H). 13 C NMR(100MHz,DMSO-d6)δ164.2,143.0,138.0,137.8,137.6,136.0,131.3,130.8,128.8, 128.1,127.1,127.0,126.8,123.5,114.5,112.2,97.5,45.5,21.0.HR-MS(ESI),calcd.C 22 H 20 N4O2,[M+H] + m / z:373.1665,found:373.1666.

[0092] Example 23

[0093] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 20, except that 4-methylphenylboronic acid in step (b) is replaced with 4-fluorophenylboronic acid, otherwise it is the same as in Example 20. Example 23 shows the preparation of an imidazo[1,2-a]pyridine derivative, a white solid with a melting point of 200-201°C, with the following structural formula: (Compound 23). The structural analysis results are as follows: 1H NMR (400MHz, DMSO-d6) δ11.14(s,1H),9.01(s,1H),8.10(s,1H),7.85(s,1H),7.70(d,J=8.0Hz, 2H),7.60-7.42(m,5H),7.26(t,J=8.7Hz,2H),6.93(s,1H),6.22(s,1H),4.62(d,J=5.9Hz,2H). 13 CNMR(100MHz,DMSO-d6)δ164.2,162.9,160.5,143.1,137.9,136.4,134.5,131.3, 128.3,126.9,125.5,115.8,115.6,114.5,112.1,96.7,45.4.HR-MS(ESI),calcd.C 21 H 17 FN4O2,[M+H] + m / z:377.1414,found:377.1417.

[0094] Example 24

[0095] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 20, except that 4-methylphenylboronic acid in step (b) is replaced with 3-fluorophenylboronic acid, otherwise it is the same as in Example 20. Example 24 shows the preparation of an imidazo[1,2-a]pyridine derivative, a white solid with a melting point of 204-206°C, with the following structural formula: (Compound 24). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ11.14(s,1H),9.00(s,1H),8.20(s,1H),7.85(s,1H),7.70(d,J=7.9Hz, 2H),7.57-7.32(m,6H),7.16(t,J=7.9Hz,1H),6.94(s,1H),6.28(s,1H),4.64(d,J=5.4Hz,2H). 13 C NMR (100MHz, DMSO-d6) δ163.8,161.4,143.1,140.5,138.1,136.4,131.5,131.1,130.8,126. 9,125.2,122.4,114.6,114.1,113.9,113.2,113.0,112.6,96.3,45.3.HR-MS(ESI),calcd.C 21 H 17 FN4O2,[M+H]+ m / z:377.1414,found:377.1411.

[0096] Example 25

[0097] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 20, except that 4-methylphenylboronic acid in step (b) is replaced with 2-fluorophenylboronic acid, otherwise the same as in Example 20. Example 25 shows the preparation of an imidazo[1,2-a]pyridine derivative, a white solid with a melting point of 206-207°C, with the following structural formula:

[0098] (Compound 25). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ11.16(s,1H),8.99(s,1H),8.17(s,1H),8.04(s,1H),7.77-7.63(m,3H) ,7.49(d,J=5.1Hz,3H),7.41(d,J=6.0Hz,1H),7.30(d,J=5.9Hz,3H),6.41(s,1H),4.60(s,2H). 13 CNMR(100MHz,DMSO-d6)δ164.6,158.4,142.8,135.4,131.9,131.1,130.4,128.5,127.5, 125.5,123.2,116.8,116.6,115.6,115.1,101.8,46.0,31.6,30.3.HR-MS(ESI),calcd.C 21 H 17 FN4O2,[M+H] + m / z:377.1414,found:377.1419.

[0099] Example 26

[0100] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which includes the following steps:

[0101] ① Weigh 5 mmol of 6-bromoimidazolo[1,2-A]pyridine-8-carboxylic acid, methyl p-aminobenzoate (5 mmol), and HATU (6 mmol) into a flask containing 20 mL of DMF; add 7.5 mmol of DIPEA with stirring, and react at room temperature for 2 h, monitored by TLC; after the reaction is complete, add the reaction system to water, and a solid slowly precipitates out. Filter to obtain compound F-1, with the structural formula […].

[0102] ② Take compound F-1 (5 mmol), 4-methylphenylboronic acid (7.5 mmol), bis(triphenylphosphine)palladium dichloride (0.5 mmol), and potassium carbonate (7.5 mmol) into a round-bottom flask containing 1,4-dioxane / water (30 mL / 3 mL); reflux at 90 °C for 5 h under nitrogen protection, and monitor by TLC; after the reaction is complete, 1,4-dioxane is evaporated, the residue is dissolved in ethyl acetate, the ethyl ester phase is concentrated, transferred to a round-bottom flask containing methanol (15 mL), 3-5 mL of 33% sodium hydroxide / water solution is added, reflux at 75 °C for 1 h, and monitor by TLC; after the reaction is complete, methanol is evaporated, acidified with hydrochloric acid, and filtered to obtain compound G-1, with the structural formula [insert structural formula here].

[0103] ③ Weigh out compound G-1 (1 mmol), O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (1 mmol), and HATU (1.2 mmol) into a round-bottom flask containing DMF (10 mL); add DIPEA (1.5 mmol) with stirring, and react at room temperature for 2 h, monitored by TLC; after the reaction is complete, add the reaction system to water, and a solid slowly precipitates out. Filter the solid and transfer it to a round-bottom flask containing dichloromethane (10 mL). Slowly add concentrated hydrochloric acid until complete deprotection; remove the dichloromethane by vortexing, add sodium bicarbonate / water solution with stirring at room temperature, adjust the pH to weakly acidic, and filter to obtain the imidazo[1,2-a]pyridine derivative of Example 26, a white solid with a melting point of 201–202 °C, and the structural formula is [insert structural formula here]. (Compound 26). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ12.60(s,1H),9.17(s,1H),8.34(s,1H),8.17(s,1H),7.8 6(s,4H),7.83(s,1H),7.63(d,J=7.6Hz,2H),7.33(d,J=7.6Hz,2H),2.37(s,3H). 13 CNMR(100MHz,DMSO-d6)δ163.7,160.7,141.5,140.7,137.6,132.8,129.8,128.3,1 28.0,127.5,127.3,126.4,125.0,119.5,119.0,114.9,20.6.HR-MS(ESI),calcd.C 22 H 18 N4O3,[M+H] + m / z:387.1457,found:387.1463.

[0104] Example 27

[0105] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that 4-methylphenylboronic acid in step ② is replaced with 3-methylphenylboronic acid, otherwise it is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 27 was prepared, a white solid with a melting point of 247-248℃, and its structural formula is as follows. (Compound 27). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ12.45(s,1H),11.23(s,1H),9.23(s,1H),9.01(s,1H),8.45(s,1H),8.21(s, 1H),7.95-7.81(m,5H),7.63-7.51(m,2H),7.43(t,J=7.6Hz,1H),7.27(d,J=7.5Hz,1H),2.42(s,3H). 13 C NMR (100MHz, DMSO-d6) δ163.8,160.8,140.7,138.6,135.4,129.1,128.9,128. 2,128.0,127.2,125.6,123.8,119.4,119.2,115.1,21.0.HR-MS(ESI),calcd.C 22 H 18 N4O3,[M+H] + m / z:387.1457,found:387.1458.

[0106] Example 28

[0107] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that 4-methylphenylboronic acid in step ② is replaced with 2-methylphenylboronic acid, otherwise the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 28 was prepared as a white solid with a melting point of 235-236°C, and its structural formula is as follows. (Compound 28). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ11.81(s,1H),11.25(s,1H),9.15(s,1H),8.64(s,1H),8.41(s,1H) ,8.09(s,1H),7.93(d,J=8.6Hz,2H),7.84(d,J=8.6Hz,2H),7.58-7.30(m,4H),2.36(s,3H). 13C NMR (100MHz, DMSO-d6) δ163.7,161.2,140.7,135.8,135.2,130.7,130.4,130. 1,128.9,128.4,127.8,126.3,119.8,118.4,115.7,19.9.HR-MS(ESI),calcd.C 22 H 18 N4O3,[M+H] + m / z:387.1457,found:387.1466.

[0108] Example 29

[0109] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that 4-methylphenylboronic acid in step ② is replaced with 4-fluorophenylboronic acid, otherwise it is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 29 was prepared, a white solid with a melting point of 234-235℃, and its structural formula is as follows. (Compound 29). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ12.59(s,1H),9.18(s,1H),8.33(s,1H),8.17(s,1H),8.00-7.58(m,7H),7.37(t,J=8.5Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ163.7,163.4,161.0,160.7,141.5,140.6,132.9,132.3,128.8,12 8.8,128.4,128.0,127.4,124.1,119.5,119.0,116.2,116.0,115.0.HR-MS(ESI),calcd.C 21 H 15 FN4O3,[M+H] + m / z:391.1206,found:391.1208.

[0110] Example 30

[0111] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that methyl p-aminobenzoate in step ① is replaced with methyl p-aminophenylacetate, otherwise it is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 30 was prepared, a white solid with a melting point of 220-221°C, and the structural formula is as follows. (Compound 30). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ11.51(s,1H),10.83(s,1H),9.48(s,1H),9.06(s,1H),8.40(d,J=1.8H z,1H),8.11(d,J=1.6Hz,1H),7.86-7.76(m,4H),7.40-7.24(m,5H),3.32(s,2H),2.37(s,3H). 13 C NMR (100MHz, DMSO-d6) δ167.0,161.0,138.6,136.6,132.3,131.3,129.8,129.2,128.2,126.9,120.6,118.7,115.9,20.7.HR-MS(ESI),calcd.C 23 H 20 N4O3,[M+H] + m / z:401.1614, found:401.1607.

[0112] Example 31

[0113] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that: methyl p-aminobenzoate in step ① is replaced with methyl p-aminophenylacetate, and 4-methylphenylboronic acid in step ② is replaced with 3-methylphenylboronic acid, the rest is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 31 was prepared, a white solid with a melting point of 206-207℃, and the structural formula is as follows. (Compound 31). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ12.13(s,1H),10.73(s,1H),9.25(s,1H),8.86(s,1H),8.51(s,1H),8.22(s,1H),7.91(s, 1H),7.75(d,J=8.3Hz,2H),7.65-7.54(m,2H),7.44(t,J=7.6Hz,1H),7.38-7.23(m,3H),3.37(s,2H),2.42(s,3H). 13 C NMR (100MHz, DMSO-d6) δ167.0,160.5,138.6,136.7,135.4,132.0,129.5,129.1,127.9,127.3,123.8,119.9,119.7,115.2,21.0.HR-MS(ESI),calcd.C23 H 20 N4O3,[M+H] + m / z:401.1614, found:401.1607.

[0114] Example 32

[0115] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that: methyl p-aminobenzoate in step ① is replaced with methyl p-aminophenylacetate, and 4-methylphenylboronic acid in step ② is replaced with 2-methylphenylboronic acid, the rest is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 32 was prepared, a white solid with a melting point of 231-232℃, and the structural formula is as follows. (Compound 32). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ11.46(s,1H),10.78(s,1H),9.15(s,1H),8.66(s,1H),8.41(s ,1H),8.10(s,1H),7.77(d,J=8.3Hz,2H),7.55-7.21(m,6H),3.47(s,2H),2.36(s,3H). 13 C NMR (100MHz, DMSO-d6) δ167.0,160.8,136.6,135.8,132.3,130.7,130.1,129.3,128.9,126.3,120.3,118.5,115.7,20.0.HR-MS(ESI),calcd.C 23 H 20 N4O3,[M+H] + m / z:401.1614, found:401.1607.

[0116] Example 33

[0117] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that: methyl p-aminobenzoate in step ① is replaced with methyl p-aminophenylacetate, and 4-methylphenylboronic acid in step ② is replaced with 4-fluorophenylboronic acid, the rest is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 33 was prepared, a white solid with a melting point of 222-223℃, and the structural formula is as follows. (Compound 33). The structural analysis results are as follows: 1H NMR(400MHz,DMSO-d6)δ11.57(s,1H),10.81(s,1H),9.48(s,1H),9.05(s,1H),8.4 0(s,1H),8.20-7.94(m,3H),7.80(d,J=8.4Hz,2H),7.53-7.18(m,4H),3.88(s,2H). 13 C NMR (100MHz, DMSO-d6) δ167.0,163.9,161.4,160.9,136.6,132.3,130.9,129.5,129.3,128.7,120.5,118.8,116.6,116.1.HR-MS(ESI),calcd.C 22 H 17 FN4O3,[M+H] + m / z:405.1363, found:405.1356.

[0118] Example 34

[0119] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that methyl p-aminobenzoate in step ① is replaced with methyl p-aminomethylbenzoate, otherwise the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 34 was prepared, a white solid with a melting point of 229-230℃, and the structural formula is as follows. (Compound 34). The structural analysis results are as follows: 1 H NMR (400MHz, DMSO-d6) δ11.20(s,1H),10.60(s,1H),9.08(d,J=42.2Hz,2H),8.30(s,1H),8.13(s,1H),7.76(s,1H), 7.74(s,2H),7.64(d,J=7.1Hz,2H),7.47(d,J=7.9Hz,2H),7.34(d,J=7.3Hz,2H),4.75(d,J=5.5Hz,2H),2.37(s,3H). 13 C NMR(100MHz,DMSO-d6)δ162.5,142.3,141.7,137.5,133.0,131.6,129.8,127.3,1 27.1,127.0,126.9,126.4,124.8,119.7,114.7,42.5,20.7.HR-MS(ESI),calcd.C 23 H 20 N4O3,[M+H] +m / z:401.1614, found:401.1607.

[0120] Example 35

[0121] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that: methyl p-aminobenzoate in step ① is replaced with methyl p-aminomethylbenzoate, and 4-methylphenylboronic acid in step ② is replaced with 3-methylphenylboronic acid, the rest is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 35 was prepared, a white solid with a melting point of 224-225℃, and the structural formula is as follows. (Compound 35). The structural analysis results are as follows: 1 H NMR(400MHz,DMSO-d6)δ11.21(s,1H),10.54(s,1H),9.21(s,1H),9.02(s,1H),8.41(s,1H),8.17(s,1H),7.87 -7.70(m,3H),7.65-7.52(m,2H),7.51-7.39(m,3H),7.27(d,J=7.4Hz,1H),4.74(d,J=5.7Hz,2H),2.41(s,3H). 13 C NMR (100MHz, DMSO-d6) δ164.0,162.5,142.2,138.5,135.6,131.6,129.2,128. 9,127.5,127.3,127.1,123.8,119.5,114.9,42.5,21.0.HR-MS(ESI),calcd.C 23 H 20 N4O3,[M+H] + m / z:401.1614, found:401.1607.

[0122] Example 36

[0123] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that: methyl p-aminobenzoate in step ① is replaced with methyl p-aminomethylbenzoate, and 4-methylphenylboronic acid in step ② is replaced with 2-methylphenylboronic acid, the rest is the same as in Example 26. The imidazo[1,2-a]pyridine derivative of Example 36 was prepared, a white solid with a melting point of 225-226℃, and the structural formula is as follows. (Compound 36). The structural analysis results are as follows: 1H NMR(400MHz,DMSO-d6)δ11.21(s,1H),10.53(s,1H),9.02(s,1H),8.90(s,1H),8.13(d,J =36.9Hz,2H),7.86-7.68(m,3H),7.53-7.28(m,6H),4.73(d,J=5.7Hz,2H),2.30(s,3H). 13 C NMR (100MHz, DMSO-d6) δ164.0,162.4,142.2,136.2,135.5,131.6,130.6,129. 9,129.2,128.4,127.2,126.3,118.9,114.7,42.5,19.9.HR-MS(ESI),calcd.C 23 H 21 N4O3,[M+H] + m / z:401.1614, found:401.1607.

[0124] Example 37

[0125] This embodiment provides an imidazo[1,2-a]pyridine derivative, the preparation method of which is basically the same as that of Example 26, except that: methyl p-aminobenzoate in step ① is replaced with methyl p-aminomethylbenzoate, and 4-methylphenylboronic acid in step ② is replaced with 4-fluorophenylboronic acid, the rest is the same as in Example 26. Example 37 shows the preparation of an imidazo[1,2-a]pyridine derivative, a white solid with a melting point of 225-226℃, with the following structural formula: (Compound 37. Structural analysis results are as follows:) 1 H NMR(400MHz,DMSO-d6)δ11.21(s,1H),10.53(s,1H),9.02(s,1H),8.90(s,1H),8.13(d,J =36.9Hz,2H),7.86-7.68(m,3H),7.53-7.28(m,6H),4.73(d,J=5.7Hz,2H),2.30(s,3H). 13 C NMR (100MHz, DMSO-d6) δ164.0,162.4,142.2,136.2,135.5,131.6,130.6,129. 9,129.2,128.4,127.2,126.3,118.9,114.7,42.5,19.9.HR-MS(ESI),calcd.C 23 H 21 N4O3,[M+H] + m / z:401.1614, found:401.1607.

[0126] Experimental Example 1

[0127] The inhibitory activity of the imidazo[1,2-a]pyridine derivatives obtained in Examples 1-37 against HDAC6 at a concentration of 100 nM and their protective activity against cardiomyocytes at a concentration of 10 μM were determined.

[0128] The HDAC6 enzyme inhibition assays of compounds 1-37 in Examples were performed by Shanghai Baonuo-Sandia Company. H9c2 cells were pretreated with compounds 1-37 at a concentration of 10 μM for 24 h, then exposed to H2O2 (300 μM) for 1.5 h, and finally cell viability was measured. The single-point inhibition rate of compounds 1-37 against HDAC6 at 100 nM and their protective activity against cardiomyocytes at 10 μM were evaluated, and the results are shown in Table 1.

[0129] In Table 1, a H9c2 cells were pretreated with a 10 μM compound for 24 h, then exposed to H2O2 (300 μM) for 1.5 h, and finally cell viability was measured (H2O2 interference was excluded during drug screening). Data are expressed as mean ± standard deviation of three independent experiments. * P < 0.05 vs H2O2. “Compd. + H2O2 (%)” indicates the survival rate of myocardial cells in the presence of the compound pretreatment; “H2O2 (%)” indicates the survival rate of myocardial cells in the absence of the compound pretreatment; “PF” represents the ratio of myocardial cell survival rates in the presence / absence of the compound pretreatment. SAHA is an HDAC inhibitory control drug.

[0130] Table 1. HDAC6 inhibition rate and cardioprotective activity of the compounds prepared in Examples 1-37

[0131]

[0132]

[0133] As shown in Table 1, the imidazo[1,2-a]pyridine derivatives provided by this invention all exhibit certain HDAC6 inhibitory and cardioprotective effects. Among them, the compounds obtained in Examples 34-37 show significantly better HDAC6 inhibitory and cardioprotective effects than SAHA.

[0134] Experimental Example 2

[0135] Further HDAC6 inhibitory activity tests (IC50 values ​​calculated using SPSS) and cardioprotective activity rescreening at lower concentrations were performed on the compounds obtained in Examples 34–37. The results are shown in Table 2. In Table 2, αH9c2 cells were pretreated with 10 μM of the compound for 24 h, then exposed to H2O2 (300 μM) for 1.5 h, and finally cell viability was measured (H2O2 interference was excluded in drug screening). Data are expressed as mean ± standard deviation of three independent experiments. *P < 0.05 vs H2O2. “Compd. + H2O2 (%)” indicates the survival rate of myocardial injury cells with the presence of the compound pretreatment; “H2O2 (%)” indicates the survival rate of myocardial injury cells without the presence of the compound pretreatment; “PF” represents the ratio of myocardial injury cell survival rates with / without the presence of the compound pretreatment.

[0136] Table 2. HDAC6 inhibitory activity and cardioprotective activity of the compounds prepared in Examples 34-37.

[0137]

[0138] The results in Table 2 show that the compounds prepared in Examples 34–37 all maintained single-digit nanomolar levels of HDAC6 inhibitory activity, and still maintained excellent cardiomyocyte protection at lower concentrations.

[0139] Experimental Example 3

[0140] Press 1×10 6 One cell per mouse was used to inoculate a gastrointestinal tumor cell line into nude mice (5 weeks old), and measurements were taken. When the transplanted tumor reached 100 mm in length... 3 Mice were divided into four groups: ① Control group, 0 mg / kg / day, intraperitoneally injected with saline; ② 25 mg / kg / day, intraperitoneally administered the compound of Example 37; ③ 50 mg / kg / day, intraperitoneally administered the compound of Example 37; ④ 25 mg / kg / day, intraperitoneally administered SAHA. During a 28-day cycle of 5 consecutive days of administration followed by 2 days of rest, the weight and tumor volume of the nude mice were measured and recorded on days 1, 5, 9, 13, 17, 21, and 25. After the last day of administration, the mice were sacrificed, the transplanted tumors were dissected, weighed, and the hearts were harvested for HE staining.

[0141] Test results showed that the mouse body weight did not change significantly throughout the test, indicating that the imidazo[1,2-a]pyridine derivatives provided by this invention are non-toxic to nude mice. Tumor volume growth experiments showed that the high-concentration group grew significantly slower than the control and low-concentration groups. Tumor weight data showed that the tumor weight in the low-concentration group did not change significantly compared to the control group, while the tumor weight in the high-concentration group decreased significantly compared to the control group. HE staining results showed that the myocardial fibers were neatly arranged, without obvious lesions, cell necrosis, or inflammatory cell infiltration, suggesting that the drug has no significant myocardial toxicity. Therefore, the imidazo[1,2-a]pyridine derivatives provided by this invention can inhibit tumor proliferation at high concentrations and have no significant cardiotoxicity.

[0142] Experimental Example 4

[0143] A rat model of myocardial ischemia-reperfusion was established by ligating the left anterior descending coronary artery (LAD) for 30 min and then reperfusing for 24 h. Rats were divided into six groups: ① Control group (0 mg / kg / day, intraperitoneal injection of saline); ② Model group + 0 mg / kg / day, intraperitoneal injection of saline; ③ Model group + 2.5 mg / kg / day, oral gavage of the compound from Example 37; ④ Model group + 5 mg / kg / day, oral gavage of the compound from Example 37; ⑤ Model group + 10 mg / kg / day, oral gavage of the compound from Example 37; ⑥ Model group + 10 mg / kg / day SAHA, oral gavage. The administration was continued for 2 weeks. Except for the control group, all other rats received multiple subcutaneous injections of ISO (100 mg / kg) over 24 h for 2 days (12 h intervals) to induce acute myocardial infarction.

[0144] The test results showed that the myocardial infarction area was significantly increased in rats in the myocardial ischemia-reperfusion group compared with the sham-operated group. In the myocardial ischemia-reperfusion group, the myocardial infarction area was significantly and dose-dependently reduced in the oral gavage group. Compared with the sham-operated group, the surgical group showed leukocyte infiltration, extensive myocardial necrosis, and severe edema. This indicates that the therapeutic dose in the oral gavage group significantly alleviated these pathological changes, thus demonstrating that the imidazo[1,2-a]pyridine derivative provided in this invention has a good therapeutic effect on myocardial infarction.

[0145] In summary, the imidazo[1,2-a]pyridine derivatives provided by this invention have good inhibitory effects on HDAC6, and also have anti-tumor and cardioprotective effects. They can be used to prepare anti-tumor drugs or cardioprotective drugs, and are especially suitable for HDAC6 small molecule inhibitors.

[0146] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. Other embodiments can be obtained based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. An imidazo[1,2-a]pyridine derivative, characterized in that, Compounds with the structure shown in Formula I, Formula II, or Formula III: ; In Formulas I, II, and III, n1 and n2 are 0 or 1; X is CH or N; R1 is one of H, 2-F, 2-Cl, or 2-CH3; and R2 is one of 4-CH3, 3-CH3, 2-CH3, 4-CH2CH3, 2-CH2CH3, 4-CH(CH3)2, 4-OCH3, 2-OCH3, 2,4-(OCH3)2, 4-F, 3-F, 2-F, 3-Cl, 2-Cl, or 3-Br.

2. The imidazo[1,2-a]pyridine derivative according to claim 1, characterized in that, Compounds selected from the following structures: 。 3. A method for preparing the imidazo[1,2-a]pyridine derivative as described in claim 1, characterized in that, The method for preparing the imidazo[1,2-a]pyridine derivative with the structure shown in Formula I includes the following steps: (1) 2-Amino-5-bromonicaraldehyde, chloroacetaldehyde, and a first good solvent were mixed and subjected to a first cyclization reaction to obtain compound A, with the structural formula as follows: ; (2) Compound A, phenylboronic acids with different substitutions, a first catalyst, and a second good solvent were mixed and subjected to a first coupling reaction to obtain compound B, with the structural formula as follows: ; (3) Compound B, methyl 4-amino(substituted)benzoate or methyl 4-amino(substituted)pyridinecarboxylate, a second catalyst, a first reducing agent, sodium hydroxide, and a third good solvent are mixed to carry out a first substitution reaction to obtain compound C, with the structural formula as follows: ; (4) Compound C, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine, a third catalyst, and a fourth good solvent are mixed and subjected to a first condensation reaction to obtain an imidazo[1,2-a]pyridine derivative having the structure shown in Formula I, with the structural formula as follows: In Formula I, n1 is 0; n2 is 0; X is CH or N; R1 is one of H, 2-F, 2-Cl, and 2-CH3; R2 is one of 4-CH3, 3-CH3, 2-CH3, 4-CH2CH3, 2-CH2CH3, 4-CH(CH3)2, 4-OCH3, 2-OCH3, 2,4-(OCH3)2, 4-F, 3-F, 2-F, 3-Cl, 2-Cl, and 3-Br. The method for preparing the imidazo[1,2-a]pyridine derivative with the structure shown in Formula II includes the following steps: (a) A second substitution reaction was carried out by mixing 6-bromoimidazolo[1,2-a]pyridine-8-amine, methyl p-bromomethylbenzoate, a fourth catalyst, and a fifth good solvent to give compound D, with the structural formula: ; (b) Compound D, phenylboronic acids with different substitutions, a first catalyst, and a second good solvent were mixed to carry out a second coupling reaction to obtain compound E, with the structural formula as follows: ; (c) Compound E, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine, a third catalyst, and a fourth good solvent are mixed and subjected to a second condensation reaction to obtain an imidazo[1,2-a]pyridine derivative having the structure shown in Formula II, with the structural formula as follows: In formula II, n1 is 0; n2 is 1; X is CH; R1 is H; R2 is one of 4-CH3, 3-CH3, 2-CH3, 4-F, 3-F, and 2-F. The method for preparing the imidazo[1,2-a]pyridine derivative with the structure shown in Formula III includes the following steps: ① A mixture of 6-bromoimidazolo[1,2-A]pyridine-8-carboxylic acid, amines with different substitutions, a first catalyst, and a second good solvent is subjected to a third condensation reaction to yield compound F, with the structural formula: ; ② Compound F, phenylboronic acids with different substitutions, the first catalyst, and the second good solvent are mixed and subjected to a third coupling reaction to obtain compound G, with the structural formula as follows: ; ③ Compound G, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine, a third catalyst, and a fourth good solvent are mixed and subjected to a fourth condensation reaction to obtain an imidazo[1,2-a]pyridine derivative with the structure shown in Formula III, the structural formula of which is: In formula III, n1 is 0 or 1; n2 is 0 or 1; X is CH; R1 is H; R2 is one of 4-CH3, 3-CH3, 2-CH3, and 4-F.

4. The method for preparing imidazo[1,2-a]pyridine derivatives according to claim 3, characterized in that, The temperature of the first cyclization reaction is 80~100℃, and the reaction time is 4~8h; the temperature of the first coupling reaction, the second coupling reaction, and the third coupling reaction is 75~100℃, and the reaction time is 3~12h; the temperature of the first substitution reaction and the second substitution reaction is 0~25℃, and the reaction time is 7~12h; the temperature of the first condensation reaction, the second condensation reaction, and the third condensation reaction is 15~30℃, and the reaction time is 2~10h.

5. The method for preparing imidazo[1,2-a]pyridine derivatives according to claim 3, characterized in that, The first good solvent, the second good solvent, the third good solvent, and the fourth good solvent are each independently selected from one or more of ethanol, methanol, 1,2-dichloroethane, dichloromethane, tetrahydrofuran, N,N-dimethylformamide, dioxane, and water.

6. The method for preparing imidazo[1,2-a]pyridine derivatives according to claim 3, characterized in that, The first catalyst is selected from one or more of bis(triphenylphosphine)palladium dichloride, tetratriphenylphosphine palladium, and palladium acetate; the second catalyst is acetic acid; and the first reducing agent is selected from one or more of sodium borohydride acetate, sodium triacetoxyborohydride, and sodium borohydride.

7. The method for preparing imidazo[1,2-a]pyridine derivatives according to claim 3, characterized in that, The third catalyst is selected from one or more of HATU, DIPEA, DCC, and EDCI; the fourth catalyst is selected from one or more of sodium hydride, lithium hydroxide, and potassium hydroxide.

8. The use of an imidazo[1,2-a]pyridine derivative as described in claim 1 or 2 in the preparation of HDAC6 inhibitors.

9. The use of an imidazo[1,2-a]pyridine derivative as described in claim 1 or 2 in the preparation of a drug targeting HDAC6 for treating gastrointestinal tumors.

10. The use of an imidazo[1,2-a]pyridine derivative as described in claim 1 or 2 in the preparation of a cardioprotective drug targeting HDAC6.